2256 Stock Overview
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Abbisko Cayman Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.56 |
| 52 Week High | HK$4.69 |
| 52 Week Low | HK$2.05 |
| Beta | 1.56 |
| 1 Month Change | 27.60% |
| 3 Month Change | 53.45% |
| 1 Year Change | 29.45% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.29% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation
Apr 27
An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued
Jan 09Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?
Nov 01We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth
Jun 08Shareholder Returns
| 2256 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 7.2% | 4.8% | 2.2% |
| 1Y | 29.5% | -34.7% | -7.9% |
Return vs Industry: 2256 exceeded the Hong Kong Biotechs industry which returned -34.7% over the past year.
Return vs Market: 2256 exceeded the Hong Kong Market which returned -7.9% over the past year.
Price Volatility
| 2256 volatility | |
|---|---|
| 2256 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2256's share price has been volatile over the past 3 months.
Volatility Over Time: 2256's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 258 | Yao-Chang Xu | www.abbisko.com |
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company’s product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services.
Abbisko Cayman Limited Fundamentals Summary
| 2256 fundamental statistics | |
|---|---|
| Market cap | HK$2.31b |
| Earnings (TTM) | -HK$467.62m |
| Revenue (TTM) | HK$20.65m |
111.7x
P/S Ratio-4.9x
P/E RatioIs 2256 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2256 income statement (TTM) | |
|---|---|
| Revenue | CN¥19.06m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥19.06m |
| Other Expenses | CN¥450.64m |
| Earnings | -CN¥431.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,264.34% |
| Debt/Equity Ratio | 0% |
How did 2256 perform over the long term?
See historical performance and comparison